

Figure 1

Powder X-Ray Diffraction (PXRD) pattern for *trans*-4-[[3-[5-[[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino)methyl]-1H-1,2,3-benzotriazol-1-yl]propyl](methyl)amino] cyclohexyl hydroxy(di-2-thienyl)acetate saccharinate.




Figure 2

¹H-NMR (500 MHz, MeOD - d4) for *trans*-4-[(3-[5-[[[(2*R*)-2-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl]ethyl]amino)methyl]-1*H*-1,2,3-benzotriazol-1-yl]propyl}(methyl)amino] cyclohexyl hydroxy(di-2-thienyl)acetate saccharinate




Figure 3

Thermogravimetric (TG) and Differential scanning calorimetry (DSC) analysis of *trans*-4-[[3-[5-[[[(2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-(1*H*-1,2,3-benzotriazol-1-yl]propyl}[(methyl)amino] cyclohexyl hydroxy(di-2-thienyl)acetate saccharinate.




Figure 4

X-ray diffraction (PXRD) pattern for *trans*-4-[[3-[6-[[[(2*R*)-2-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino]methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl]propyl](methyl)-amino]cyclohexyl hydroxy(di-2-thienyl)acetate fumarate.




Figure 5
¹H-NMR spectrum (400 MHz, d₆-DMSO) for *trans*-4-[[3-[6-[[[(2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino]methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl]propyl](methyl)cyclohexyl hydroxy(cyclohexyl)acetate fumarate.




Figure 6

DSC analysis for *trans*-4-[[3-[6-[[[(2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino]methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl]propyl](methyl)-amino]cyclohexyl hydroxy(di-2-thienyl)acetate fumarate




Figure 7

TG analysis for *trans*-4-[[3-[6-[[[(2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino]methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl]propyl]-(methyl)-amino]cyclohexyl hydroxy(di-2-thienyl)acetate fumarate.

